Investor Presentaiton

" EM, Europe and API Emerging Markets $ Mn 80 70 50 10 BRO 20 72 70 -3% 60 0 Q1 FY18 Q1 FY19 Cipla Europe $ Mn $ Mn API 32252 30 35 26 30 30 -21% 20 25 +48% 20 15 20 20 20 15 10 5 0 Q1 FY18 Q1 FY19 10 5 0 Q1 FY18 Q1 FY 19 ANZ Portfolio: Azacitidine injection approved in Australia; Dymista launched in NZ Morocco: Pharma status received for Cipla Morocco plant Colombia: 5 new product launches and 4 approvals Europe Hospital segment strategy execution with Bosentan as the first product UK FPSM: Continued traction with channel partners ■ Continued momentum in seedings and lock-ins Respiratory continues to be the largest component (36% of overall) of the business Investor Presentation: Q1FY19 08-08-2018 10

View entire presentation